Luca Barcella
A5020231170- Venous Thromboembolism Diagnosis and Management
- Complement system in diseases
- COVID-19 Clinical Research Studies
- Platelet Disorders and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Atrial Fibrillation Management and Outcomes
- Renal Diseases and Glomerulopathies
- SARS-CoV-2 and COVID-19 Research
- Blood Coagulation and Thrombosis Mechanisms
- Antiplatelet Therapy and Cardiovascular Diseases
- Long-Term Effects of COVID-19
- Blood groups and transfusion
- Dermatological and COVID-19 studies
- Autoimmune Bullous Skin Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Inflammatory Biomarkers in Disease Prognosis
- Chemotherapy-induced cardiotoxicity and mitigation
- Diagnosis and Treatment of Venous Diseases
- Hemoglobinopathies and Related Disorders
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Erythrocyte Function and Pathophysiology
- Genetic Syndromes and Imprinting
- Cardiac Valve Diseases and Treatments
- Chemotherapy-related skin toxicity
Ospedale Papa Giovanni XXIII
2014-2025
Mario Negri Institute for Pharmacological Research
2009
University of Brescia
2004
Background and objectives The effect of mammalian target rapamycin (mTOR) inhibitors has never been tested in patients with autosomal dominant polycystic kidney disease (ADPKD) severe renal insufficiency. Design, setting, participants, & measurements In this academic, prospective, randomized, open label, blinded end point, parallel group trial (ClinicalTrials.gov no. NCT01223755), 41 adults ADPKD, CKD stage 3b or 4, proteinuria ≤0.5 g/24 h were randomized between September 2010 March...
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmonary complications; in particular, it may predispose to thromboembolic disease. The current guidelines recommend the use of thromboprophylaxis patients COVID-19, however, optimal heparin dosage treatment is not well-established. We conducted a multicentre, Italian, retrospective, observational study on admitted ordinary wards, describe clinical characteristic at admission, bleeding thrombotic...
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening immune-mediated microangiopathy. Daily therapeutic plasma exchange (TPE) and the optimized use of rituximab have strikingly improved outcome this disease, however rate disease recurrence remains high. Specific predictors relapse in patients remission can be relevant for an optimal patient management. In study, we aimed to identify predictive variables multicenter cohort 74 out 153 iTTP patients. They were tested...
(1) Background: Venous thromboembolism (VTE) is a frequent complication in ambulatory lung cancer patients during chemotherapy and associated with increased mortality. (2) Methods: We analyzed 568 newly diagnosed metastatic prospectively enrolled the HYPERCAN study. Blood samples collected before were tested for thrombin generation (TG) panel of hemostatic biomarkers. The Khorana risk score (KRS), new-Vienna CATS, PROTECHT, CONKO assessment models (RAMs) applied. (3) Results: Within 6...
Clozapine, an atypical antipsychotic, can cause potentially life-threating side effects such as agranulocytosis. Our case presents a picture of severe anemia without any depression the white cells or platelet lines. A 36-year-old man with treatment-resistant schizophrenia was admitted to Psychiatric Unit for therapy assessment. After admission, he gradually switched clozapine treatment, 400 mg/d. General laboratory test results were normal, hemoglobin (Hb) level 15.2 g/dL. The Hb decreased...
In hemophilia and von Willebrand disease, the degree of alteration laboratory assays correlates with bleeding manifestations. Few studies have assessed predictive value for in patients inherited platelet function disorders (IPFDs).
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy (TMA) requiring urgent treatment. Standardization of its diagnosis and optimal management challenging. This study aimed to evaluate the role centralized, rapid testing ADAMTS13 in patients experiencing acute TMAs plasma-exchange (PEX) estimate incidence TTP large Italian Region.We perfomed cohort frame project "Set-up Lombardy network for treatment undergoing apheresis", including 11 transfusion...
Background Vitamin K antagonists (VKAs) reduce thromboembolism in patients with mechanical prosthetic heart valves (MPHV). It is unclear whether a sex-based difference MPHV regarding valve site, anticoagulation quality, and mortality risk does exist. Methods We analysed 2111 from the nationwide PLECTRUM study promoted by Italian Federation of Anticoagulation Clinics (FCSA). site MPHV, as assessed time therapeutic range (TiTR), women men. Results The mean age was 56.8 ± 12.3 years. Women were...